{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:33:47Z","timestamp":1787027627150,"version":"build-2736575974"},"reference-count":55,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Farrell Family Foundation Fund","award":["PJ03176"],"award-info":[{"award-number":["PJ03176"]}]},{"name":"Farrell Family Foundation Fund","award":["T32CA163177"],"award-info":[{"award-number":["T32CA163177"]}]},{"name":"Farrell Family Foundation Fund","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}]},{"name":"UVA Cancer Training Program","award":["PJ03176"],"award-info":[{"award-number":["PJ03176"]}]},{"name":"UVA Cancer Training Program","award":["T32CA163177"],"award-info":[{"award-number":["T32CA163177"]}]},{"name":"UVA Cancer Training Program","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}]},{"name":"UVA Cancer center support grant CCSG","award":["PJ03176"],"award-info":[{"award-number":["PJ03176"]}]},{"name":"UVA Cancer center support grant CCSG","award":["T32CA163177"],"award-info":[{"award-number":["T32CA163177"]}]},{"name":"UVA Cancer center support grant CCSG","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Pancreatic cancer is the third leading cause of cancer-related death in the US. First-line chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC) include FOLFIRINOX or gemcitabine (Gem) with or without paclitaxel (Ptx); however, 5-year survival with these regimens remains poor. Previous work has demonstrated protein arginine methyltransferase 5 (PRMT5) to be a promising therapeutic target in combination with Gem for the treatment of PDAC; however, these findings have yet to be confirmed in relevant preclinical models of PDAC. To test the possibility of PRMT5 as a viable therapeutic target, clinically relevant orthotopic and metastatic patient-derived xenograft (PDX) mouse models of PDAC growth were utilized to evaluate the effect of PRMT5 knockout (KO) or pharmacologic inhibition on treatment with Gem alone or Gem with Ptx. Primary endpoints included tumor volume, tumor weight, or metastatic tumor burden as appropriate. The results showed that Gem-treated PRMT5 KO tumors exhibited decreased growth and were smaller in size compared to Gem-treated wild-type (WT) tumors. Similarly, the Gem-treated PRMT5 KO metastatic burden was lower than the Gem-treated WT metastatic burden. The addition of a PRMT5 pharmacologic inhibitor to Gem and Ptx therapy resulted in a lower final tumor weight and fewer metastatic tumors. The depletion of PRMT5 results in increased DNA damage in response to Gem and Ptx treatment. Thus, PRMT5 genetic depletion or inhibition in combination with Gem-based therapy improved the response in primary and metastatic PDAC in clinically relevant mouse models, suggesting that PRMT5 is a viable therapeutic target for combination therapy in PDAC.<\/jats:p>","DOI":"10.3390\/biom15070948","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:55:43Z","timestamp":1751442943000},"page":"948","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1327-4061","authenticated-orcid":false,"given":"Xiaolong","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-4252","authenticated-orcid":false,"given":"Sara J.","family":"Adair","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbajeet","family":"Nagdas","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-1848","authenticated-orcid":false,"given":"Todd W.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","first-page":"5632","article-title":"Protease activity-based nanobiosensors for early detection of pancreatic cancer","volume":"12","author":"Agarwal","year":"2024","journal-title":"Med. Res. Arch."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","article-title":"Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Tempero","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5306\/wjco.v7.i1.27","article-title":"Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians","volume":"7","author":"Spadi","year":"2016","journal-title":"World J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1038\/s41467-018-06676-2","article-title":"CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response","volume":"9","author":"Szlachta","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28068","DOI":"10.1073\/pnas.2009899117","article-title":"Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells","volume":"117","author":"Wei","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Xiao, W., Chen, X., Liu, L., Shu, Y., Zhang, M., and Zhong, Y. (2019). Role of protein arginine methyltransferase 5 in human cancers. Biomed. Pharmacother., 114.","DOI":"10.1016\/j.biopha.2019.108790"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/s41467-022-31645-1","article-title":"PRMT5 activates AKT via methylation to promote tumor metastasis","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12964-019-0344-4","article-title":"PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7\/cMyc axis","volume":"17","author":"Qin","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","article-title":"Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","article-title":"PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies","volume":"3","author":"Carter","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bhandari, K., and Ding, W.Q. (2024). Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073958"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: A review","volume":"5","author":"Feustel","year":"2022","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102961","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: Results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3748\/wjg.v18.i12.1286","article-title":"Mouse models of pancreatic cancer","volume":"18","author":"Hijona","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-11-0261","article-title":"Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment","volume":"10","author":"Stokes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Walters, D.M., Stokes, J.B., Adair, S.J., Stelow, E.B., Borgman, C.A., Lowrey, B.T., Xin, W., Blais, E.M., Lee, J.K., and Papin, J.A. (2013). Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077065"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.neo.2014.06.004","article-title":"Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer","volume":"16","author":"Lindberg","year":"2014","journal-title":"Neoplasia"},{"key":"ref_28","unstructured":"NRC (2011). Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals, National Academies Press. [8th ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1245\/s10434-016-5116-4","article-title":"Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis","volume":"23","author":"Newhook","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-17-2283","article-title":"CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer","volume":"24","author":"Michaels","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_31","first-page":"1977","article-title":"Murine bioluminescent hepatic tumour model","volume":"41","author":"Rajendran","year":"2010","journal-title":"J. Vis. Exp."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0959-8049(02)00410-0","article-title":"Advancing animal models of neoplasia through in vivo bioluminescence imaging","volume":"38","author":"Edinger","year":"2002","journal-title":"Eur. J. Cancer."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bmcl.2019.03.042","article-title":"Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors","volume":"29","author":"Lin","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"\u03b3H2AX: A sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.dnarep.2021.103243","article-title":"Recent advances in \u03b3H2AX biomarker-based genotoxicity assays: A marker of DNA damage and repair","volume":"108","author":"Rahmanian","year":"2021","journal-title":"DNA Repair"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/apc.2020.03.03","article-title":"Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma","volume":"3","author":"He","year":"2020","journal-title":"Ann. Pancreat. Cancer."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer\u2014Clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrclinonc.2009.236","article-title":"Advanced pancreatic carcinoma: Current treatment and future challenges","volume":"7","author":"Stathis","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","unstructured":"Medicine USNLo (2025, May 08). Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06922591."},{"key":"ref_41","unstructured":"Medicine USNLo (2025, May 08). Safety and Tolerability of TNG456 Alone and in Combination with Abemaciclib in Patients with Solid Tumors with MTAP Loss, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06810544."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pawar, J.S., Al-Amin, M.Y., and Hu, C.D. (2023). JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1126482"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.21873\/anticanres.17351","article-title":"MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Induces Cell Cycle Arrest and Synergizes with Oxaliplatin and Gemcitabine for Enhanced Anticancer Effects","volume":"44","author":"Soeta","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ayoub, N.M. (2021). Editorial: Novel Combination Therapies for the Treatment of Solid Cancers. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.708943"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","article-title":"Replication Catastrophe: When a Checkpoint Fails because of Exhaustion","volume":"66","author":"Toledo","year":"2017","journal-title":"Mol. Cell."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12013-013-9530-y","article-title":"A Relationship Between Replication Protein A and Occurrence and Prognosis of Esophageal Carcinoma","volume":"67","author":"Dahai","year":"2013","journal-title":"Cell Biochem. Biophys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/modpathol.3800719","article-title":"Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer","volume":"20","author":"Givalos","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-14-0306","article-title":"RPA inhibition increases replication stress and suppresses tumor growth","volume":"74","author":"Glanzer","year":"2014","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jcp.20622","article-title":"Functions of human replication protein A (RPA): From DNA replication to DNA damage and stress responses","volume":"208","author":"Zou","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/MCB.21.1.281-288.2001","article-title":"DNA damage-dependent nuclear dynamics of the Mre11 complex","volume":"21","author":"Mirzoeva","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein Arginine Methylation in Mammals: Who, What, and Why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/cr.2011.128","article-title":"The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation","volume":"22","author":"Yu","year":"2012","journal-title":"Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.molcel.2017.01.019","article-title":"PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination","volume":"65","author":"Clarke","year":"2017","journal-title":"Mol. Cell"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/7\/948\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:43Z","timestamp":1760032903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/7\/948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["biom15070948"],"URL":"https:\/\/doi.org\/10.3390\/biom15070948","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}